PLRX analyst estimates

Pliant Therapeutics (PLRX) analyst ratings, the average price target and its range, and every firm's latest call.

PLRX analyst ratings and price targets

DateFirmCallTarget
Mar 12, 2026Piper SandlerPliant Therapeutics (PLRX) PT Lowered to $3 at Piper Sandler$3.00
Mar 3, 2025Leerink PartnersPliant Therapeutics downgraded to Market Perform from Outperform at Leerink$2.00
Mar 3, 2025Stifel NicolausPliant Therapeutics downgraded to Hold from Buy at Stifel$3.00
Sep 13, 2024H.C. WainwrightH.C. Wainwright Reiterates Buy Rating on Pliant Therapeutics (PLRX)$38.00
Sep 9, 2024Leerink PartnersPliant Therapeutics assumed with an Outperform at Leerink$33.00
May 23, 2024Piper SandlerPiper Sandler Reiterates Overweight Rating on Pliant Therapeutics (PLRX)$40.00
May 7, 2024RBC CapitalPliant Therapeutics (PLRX) PT Lowered to $45 at RBC Capital$45.00
May 7, 2024H.C. WainwrightPliant Therapeutics (PLRX) PT Lowered to $36 at H.C. Wainwright$36.00
May 7, 2024OppenheimerPliant Therapeutics (PLRX) PT Raised to $48 at Oppenheimer$48.00
May 7, 2024Stifel NicolausPliant Therapeutics (PLRX) PT Lowered to $32 at Stifel$32.00
Dec 7, 2022J.P. MorganJP Morgan Initiates Coverage On Pliant Therapeutics with Overweight Rating, Announces Price Target of $42$42.00